Dumuis A, Sebben M, Bockaert J
Centre CNRS-INSERM de Pharmacologie-Endocrinologie, Montpellier, France.
Naunyn Schmiedebergs Arch Pharmacol. 1989 Oct;340(4):403-10. doi: 10.1007/BF00167041.
We have previusly shown that a non-classical 5-hydroxytryptamine (5-HT4) receptor mediates the stimulation of adenylate cyclase activity in mouse embryo colliculi neurons in primary culture. The pharmacological characteristics of this receptor exclude the possibility that it belongs to the known 5-HT1, 5-HT2 or 5-HT3 receptor types. Here we report that this 5-HT receptor can be stimulated by 4-amino-5-chloro-2-methoxy substituted benzamide derivatives. All these compounds have been reported to be potent stimulants of gastrointestinal motility and some of them are 5-HT3 receptor antagonists. The rank order of potency of these substituted benzamide derivatives in stimulating cAMP formation was: cisapride greater than BRL 24924 greater than 5-HT greater than zacopride greater than BRL 20627 greater than metoclopramide. The non-additivity of benzamide and 5-HT activities suggests that 5-HT and the substituted benzamide derivatives act on the same receptor. Only ICS 205930, a recognized 5-HT3 receptor antagonist, competitively antagonized the stimulatory effect of cisapride, zacopride and BRL 24924. However, its pKi (6-6.3) for this new receptor was very different from its pKi for 5-HT3 receptors (pKi = 8-10). Other selective 5-HT3 receptor antagonists with an indole group (BRL 43694 and GR 38032F), with a benzoate group (cocaïne, MDL 72222) or with a piperazine group (quipazine) were ineffective in reversing the stimulatory effect of benzamide derivatives. Exposure of neuronal cells to potent agonists at this receptor such as BRL 24924 rapidly reduces its capacity to stimulate cAMP production.(ABSTRACT TRUNCATED AT 250 WORDS)
我们先前已表明,一种非经典的5-羟色胺(5-HT4)受体介导原代培养的小鼠胚胎丘脑中腺苷酸环化酶活性的刺激。该受体的药理学特性排除了它属于已知的5-HT1、5-HT2或5-HT3受体类型的可能性。在此我们报告,这种5-HT受体可被4-氨基-5-氯-2-甲氧基取代的苯甲酰胺衍生物刺激。所有这些化合物均已被报道为胃肠道动力的强效刺激剂,其中一些还是5-HT3受体拮抗剂。这些取代苯甲酰胺衍生物刺激cAMP形成的效力顺序为:西沙必利大于BRL 24924大于5-HT大于扎考必利大于BRL 20627大于甲氧氯普胺。苯甲酰胺和5-HT活性的非加和性表明5-HT和取代苯甲酰胺衍生物作用于同一受体。只有公认的5-HT3受体拮抗剂ICS 205930竞争性拮抗西沙必利、扎考必利和BRL 24924的刺激作用。然而,其对该新受体的pKi(6 - 6.3)与其对5-HT3受体的pKi(pKi = 8 - 10)非常不同。其他具有吲哚基团(BRL 43694和GR 38032F)、苯甲酸酯基团(可卡因、MDL 72222)或哌嗪基团(喹哌嗪)的选择性5-HT3受体拮抗剂在逆转苯甲酰胺衍生物的刺激作用方面无效。将神经元细胞暴露于该受体的强效激动剂如BRL 24924下会迅速降低其刺激cAMP产生的能力。(摘要截短于250字)